The optimized anticoagulation strategy in prolonged hemodialysis.
anti-Xa
anticoagulation
chronic hemodialysis
fiber clotting
nocturnal dialysis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
13
01
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
During extended (nocturnal) hemodialysis (ENHD), the dose of low-molecular-weight heparin (LMWH) can be administered as a single injection or as a divided dose over different time points. Our hypothesis was that a single injection might be sufficient to maintain dialyzer fiber patency. In addition, we investigated whether the biochemical clotting parameter anti-Xa accurately predicts fiber blocking. Our hypothesis was tested in 20 stable patients on ENHD in a random cross-over setting during two consecutive midweek sessions. The regular total dose of LMWH (i.e. enoxaparin, Clexane® 40-100 mg, Sanofi, Belgium) was either given (i) in a single injection at the dialysis start or (ii) divided over two injections, at the start and halfway the dialysis session. Blood samples were taken from the arterial blood line at different time points to determine plasma anti-Xa activity levels. Post-dialysis, the rinsed and dried hemodialyzers were scanned with a reference micro-computed tomography (µCT) scanning technique, and non-blocked fibers were counted in a central cross-section of the dialyzer outlet potting (ImageJ, NIH, USA). The percentage of open fibers in the dialyzers after a single injection of LMWH [91 (61-96)%] versus divided administration [94 (79-98)%] was not different. Time averaged anti-Xa activity levels were clinically not significantly different between both sessions. Anti-Xa activity levels correlated with the administered anticoagulation doses normalized for body weight, but not with the percentages open fibers in the dialyzers. Our results indicate that there is no need to administer enoxaparin over two injections for ENHD up to 8 h. The usefulness of monitoring anti-Xa levels to predict fiber patency, assessed by µCT, can be questioned, but further clinical trials are needed.
Sections du résumé
Background
UNASSIGNED
During extended (nocturnal) hemodialysis (ENHD), the dose of low-molecular-weight heparin (LMWH) can be administered as a single injection or as a divided dose over different time points. Our hypothesis was that a single injection might be sufficient to maintain dialyzer fiber patency. In addition, we investigated whether the biochemical clotting parameter anti-Xa accurately predicts fiber blocking.
Methods
UNASSIGNED
Our hypothesis was tested in 20 stable patients on ENHD in a random cross-over setting during two consecutive midweek sessions. The regular total dose of LMWH (i.e. enoxaparin, Clexane® 40-100 mg, Sanofi, Belgium) was either given (i) in a single injection at the dialysis start or (ii) divided over two injections, at the start and halfway the dialysis session. Blood samples were taken from the arterial blood line at different time points to determine plasma anti-Xa activity levels. Post-dialysis, the rinsed and dried hemodialyzers were scanned with a reference micro-computed tomography (µCT) scanning technique, and non-blocked fibers were counted in a central cross-section of the dialyzer outlet potting (ImageJ, NIH, USA).
Results
UNASSIGNED
The percentage of open fibers in the dialyzers after a single injection of LMWH [91 (61-96)%] versus divided administration [94 (79-98)%] was not different. Time averaged anti-Xa activity levels were clinically not significantly different between both sessions. Anti-Xa activity levels correlated with the administered anticoagulation doses normalized for body weight, but not with the percentages open fibers in the dialyzers.
Conclusion
UNASSIGNED
Our results indicate that there is no need to administer enoxaparin over two injections for ENHD up to 8 h. The usefulness of monitoring anti-Xa levels to predict fiber patency, assessed by µCT, can be questioned, but further clinical trials are needed.
Identifiants
pubmed: 37915936
doi: 10.1093/ckj/sfad125
pii: sfad125
pmc: PMC10616481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2235-2242Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
None declared.
Références
Semin Dial. 2021 Mar;34(2):103-115
pubmed: 33135208
J Am Soc Nephrol. 2004 Dec;15(12):3192-206
pubmed: 15579523
Am J Nephrol. 2019;50(4):255-261
pubmed: 31434091
Nephrology (Carlton). 2018 Apr;23(4):317-322
pubmed: 28052451
Sci Rep. 2018 Feb 8;8(1):2677
pubmed: 29422614
BMC Nephrol. 2012 Jun 28;13:50
pubmed: 22742742
Kidney Int. 2005 Aug;68(2):862-6
pubmed: 16014067
Nephrology (Carlton). 2009 Aug;14(5):455-61
pubmed: 19674314
BBA Clin. 2015 Mar 30;3:276-9
pubmed: 26672512
Sci Rep. 2022 Apr 5;12(1):5717
pubmed: 35383253
Clin Kidney J. 2016 Aug;9(4):630-5
pubmed: 27478610
Kidney Int. 1999 Oct;56(4):1578-83
pubmed: 10504511
Hemodial Int. 2020 Apr;24(2):195-201
pubmed: 31804773
Nephrol Dial Transplant. 2004 Jan;19(1):164-70
pubmed: 14671052
Am J Kidney Dis. 2002 Nov;40(5):990-5
pubmed: 12407644
Neth J Med. 2015 Jul;73(6):270-5
pubmed: 26228191
Nephrology (Carlton). 2020 Sep;25(9):723-729
pubmed: 31999031
Clin Nephrol. 2015 Nov;84(5):274-9
pubmed: 26365216
Nephron. 2017;137(3):205-211
pubmed: 28817831
Nephrol Dial Transplant. 1999 Aug;14(8):1943-7
pubmed: 10462275